CY1119860T1 - Αναστολεις φωσφοδιεστερασης για διακολπικη χρηση στη θεραπεια της στειροτητας - Google Patents

Αναστολεις φωσφοδιεστερασης για διακολπικη χρηση στη θεραπεια της στειροτητας

Info

Publication number
CY1119860T1
CY1119860T1 CY20181100107T CY181100107T CY1119860T1 CY 1119860 T1 CY1119860 T1 CY 1119860T1 CY 20181100107 T CY20181100107 T CY 20181100107T CY 181100107 T CY181100107 T CY 181100107T CY 1119860 T1 CY1119860 T1 CY 1119860T1
Authority
CY
Cyprus
Prior art keywords
treatment
inhibitors
phospheseesteration
inhibitor
administration
Prior art date
Application number
CY20181100107T
Other languages
English (en)
Inventor
Maria Carmen PARDINA PALLEJA
Miguel Ángel VAZ-ROMERO UÑA
Original Assignee
Prokrea Bcn, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokrea Bcn, S.L. filed Critical Prokrea Bcn, S.L.
Publication of CY1119860T1 publication Critical patent/CY1119860T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια νέα εφαρμογή αναστολέων φωσφοδιεστεράσης για τη θεραπεία στειρότητας ζευγών, η οποία συνιστά μια αποτελεσματική εναλλακτική λύση έναντι επεμβατικών τεχνικών υποβοηθούμενης αναπαραγωγής όπως η συζυγική τεχνητή γονιμοποίηση, και η οποία συνίσταται στη διακολπική χορήγηση ενός αναστολέα φωσφοδιεστεράσης αμέσως πριν και/ή μετά τη συνουσία. Η παρούσα εφεύρεση αναφέρεται επίσης σε φαρμακευτικές μορφές κατάλληλες για διακολπική χορήγηση αναστολέων φωσφοδιεστεράσης.
CY20181100107T 2011-06-23 2018-01-26 Αναστολεις φωσφοδιεστερασης για διακολπικη χρηση στη θεραπεια της στειροτητας CY1119860T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131059A ES2395801B1 (es) 2011-06-23 2011-06-23 "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
PCT/ES2012/070453 WO2012175775A1 (es) 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por vía transvaginal para el tratamiento de la infertilidad

Publications (1)

Publication Number Publication Date
CY1119860T1 true CY1119860T1 (el) 2018-06-27

Family

ID=46603994

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100107T CY1119860T1 (el) 2011-06-23 2018-01-26 Αναστολεις φωσφοδιεστερασης για διακολπικη χρηση στη θεραπεια της στειροτητας

Country Status (21)

Country Link
US (2) US9220679B2 (el)
EP (1) EP2724716B1 (el)
JP (2) JP6373755B2 (el)
KR (1) KR101948355B1 (el)
AU (1) AU2012273879B2 (el)
BR (1) BR112013032855A2 (el)
CA (1) CA2846498C (el)
CY (1) CY1119860T1 (el)
DK (1) DK2724716T3 (el)
ES (2) ES2395801B1 (el)
HR (1) HRP20180105T1 (el)
HU (1) HUE036489T2 (el)
LT (1) LT2724716T (el)
MX (1) MX365773B (el)
NO (1) NO2724716T3 (el)
PL (1) PL2724716T3 (el)
PT (1) PT2724716T (el)
RS (1) RS56921B1 (el)
RU (1) RU2601913C2 (el)
SI (1) SI2724716T1 (el)
WO (1) WO2012175775A1 (el)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
JPS5229318B2 (el) 1972-03-30 1977-08-01
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
ZA807267B (en) 1979-11-26 1981-11-25 Sterling Drug Inc 5-(pyridinyl)-2(1h)-pyridinones,useful as cardiotonic agents and their preparation
GB8607570D0 (en) * 1986-03-26 1986-04-30 Euro Celtique Sa Vaginal pharmaceutical preparation
JPH0347134A (ja) * 1989-03-08 1991-02-28 Hoechst Japan Ltd ヒドロゲル製剤およびキセロゲル製剤の製造法
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
DE19801438A1 (de) * 1998-01-16 1999-07-29 Haemopep Pharma Gmbh Verwendung von spezifischen Phosphodiesterase-Inhibitoren zur Erhöhung der Spermienmotilität
WO1999062533A1 (en) 1998-06-04 1999-12-09 Jedco Products, Llc Preparation for topical application to the male sexual organ
US20050075284A1 (en) * 2000-05-22 2005-04-07 Illana Gozes Pharmaceutical compositions comprising vip-related peptides for the treatment of sexual disorders
AU2001241730B2 (en) * 2001-02-23 2007-03-15 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
EP1404336A1 (en) * 2001-06-14 2004-04-07 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
JP4651944B2 (ja) * 2002-02-07 2011-03-16 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 殺精子剤および殺菌剤からの粘膜刺激の予防のための亜鉛塩組成物
EP1473034A1 (en) * 2003-03-17 2004-11-03 Lagow GmbH Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
JP2007522077A (ja) * 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
ES2245609B1 (es) 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
TW201444869A (zh) * 2005-06-30 2014-12-01 Abbvie Inc Ｉｌ-１２／ｐ４０結合蛋白
CN102438645A (zh) * 2009-01-13 2012-05-02 卢布里斯有限责任公司 阴道上皮界面润滑的治疗调节

Also Published As

Publication number Publication date
US20140194448A1 (en) 2014-07-10
CA2846498C (en) 2019-01-15
LT2724716T (lt) 2018-02-26
PT2724716T (pt) 2017-12-26
SI2724716T1 (en) 2018-03-30
ES2395801A1 (es) 2013-02-15
HRP20180105T1 (hr) 2018-03-23
US9220679B2 (en) 2015-12-29
HUE036489T2 (hu) 2018-07-30
MX2013015280A (es) 2014-08-01
MX365773B (es) 2019-06-10
EP2724716B1 (en) 2017-11-22
RS56921B1 (sr) 2018-05-31
JP6373755B2 (ja) 2018-08-15
RU2014101761A (ru) 2015-08-20
JP2014518221A (ja) 2014-07-28
NO2724716T3 (el) 2018-04-21
ES2395801B1 (es) 2014-06-06
RU2601913C2 (ru) 2016-11-10
CA2846498A1 (en) 2012-12-27
DK2724716T3 (en) 2018-02-12
KR20140043927A (ko) 2014-04-11
KR101948355B1 (ko) 2019-02-14
JP2017075185A (ja) 2017-04-20
AU2012273879B2 (en) 2017-04-13
PL2724716T3 (pl) 2018-04-30
JP6347858B2 (ja) 2018-06-27
EP2724716A1 (en) 2014-04-30
AU2012273879A1 (en) 2014-02-06
BR112013032855A2 (pt) 2017-01-24
ES2656204T3 (es) 2018-02-26
US20160074407A1 (en) 2016-03-17
WO2012175775A1 (es) 2012-12-27

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201391108A1 (ru) Лечение липодистрофии
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201390347A1 (ru) Лечение заболеваний
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201201201A1 (ru) Новые ингибиторы rock